The Australian National University (ANU) has announced a new research project with Janssen Research & Development, LLC, aimed at improving health outcomes in Type 1 Diabetes (T1D).

The collaboration was facilitated by Johnson & Johnson Innovation.

The project will focus on the development of new methods for measuring and monitoring disease activity. 

Type 1 Diabetes is an autoimmune disease that attacks the body’s ability to process sugar by destroying insulin-producing beta cells in the pancreas. 

Researchers from ANU will test new methods of monitoring this damage, as part of the wider effort to develop preventive measures and therapies.

Together with Janssen scientists, researchers from ANU aim to identify individuals at risk of T1D and track markers and influences in childhood to identify the opportunity and means to intervene early in the course of disease.

“The goal of this initiative is to discover avenues for interception that will enable a brighter future for individuals at risk of developing symptomatic T1D,” said Charmaine Simeonovic, Associate Professor and Chief Investigator.

“Working together with Janssen offers a fantastic opportunity for us to improve the monitoring of early stages of Type 1 diabetes disease development, so that new therapies can be better used to intervene and prevent diabetes onset.”

Improvement of health monitoring and diagnosis in Type 1 Diabetes is a priority area for ANU, as well as a focus of investment through the Our Health in Our Hands initiative and inaugural ANU Grand Challenges Scheme.

This research project will also assist partnerships held with ACT Health and clinical collaborators worldwide.  

This project builds on work supported by the JDRF Australian Type 1 Diabetes Clinical Research Network and its mission to creating a world without Type 1 Diabetes.

Top image: Adona Gonzalez/Pixabay

Contact the media team

You may also like

Article Card Image

ANU researchers closer to finding new lung cancer treatments

A new discovery could help the human immune system “see and destroy” the cells behind killer diseases like lung cancer.  

Article Card Image

ANU and Korean biotech firm set sights on finding cure for blindness 

Korean biotech company MDimune Inc. and ANU researchers are joining forces to develop new and more effective treatments for age-related macular degeneration – the leading cause of blindness in the developed world.  

Article Card Image

Women are 50–75% more likely to have adverse drug reactions. A new study helps explain why

The assumption that females are just smaller versions of males has been widely used in biomedical research. A new mouse study indicates that’s unlikely to be the case.

Subscribe to ANU Reporter

Anu Logo

+61 2 6125 5111

The Australian National University, Canberra

CRICOS Provider: 00120C

ABN: 52 234 063 906

EDX Logo
APRU Logo
IARU Logo
Group of eight Australia Logo